

Epigenetics: Technologies and Global Markets

https://marketpublishers.com/r/E7E9887223A0EN.html Date: March 2025 Pages: 115 Price: US\$ 4,650.00 (Single User License) ID: E7E9887223A0EN

Abstracts

Report Scope

This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.

In this report, BCC Research estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.

This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.

Report Includes

25 data tables and 66 additional tables



Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029

Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region

Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors

Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses

Evaluation of recent patent activity and key granted and published patents in the industry

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen



Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook Scope of Report Market Summary

CHAPTER 2 MARKET OVERVIEW

Epigenetics Overview DNA Methylation Histone Modification RNA Modifications Epigenetic Modulators

CHAPTER 3 MARKET DYNAMICS

Market Dynamics Snapshot Market Drivers Rising Prevalence of Cancer and Unmet Need in Oncology Advances in Analytical Technologies and Tools Increasing Investment in Biomedical Research Trend Towards Precision Medicine Growing Interest in Liquid Biopsy **Market Restraints** From Bench to Bedside: The Translation Gap in Epigenetics Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors Stringent Regulatory Landscape Market Trends Combining Epigenetic Modifiers with Other Therapeutic Class Multi-omics Integration Long-Read Sequencing in Epigenetic Research Epigenetic Biomarkers-based Blood Test for Cancer Screening

CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS

Emerging Technologies Epigenome Editing



Epitranscriptomics Bromodomain and Extra-Terminal Domain Inhibitors Menin Inhibitors Application Beyond Oncology Pipeline Analysis Overview Novel Epigenetic Therapeutics in Development in Phase 2 and Above

CHAPTER 5 MARKET SEGMENTATION ANALYSIS

Segmentation Breakdown Epigenetics Research Tools and Reagents Market, by Study Method Market Overview Market Size and Forecast **DNA Methylation Histone Modification RNA Modification** In Vitro Diagnostics (IVDs) Market, by Clinical Indication Market Overview Market Size and Forecast Epigenetic Therapeutics Market, by Drug Class Market Overview Market Size and Forecast Geographic Breakdown Epigenetics Research Tools and Reagents Market, by Region Market Size and Forecast North America Europe Asia-Pacific Rest of the World

CHAPTER 6 COMPETITIVE INTELLIGENCE

Research Tools and Reagents In Vitro Diagnostics Therapeutics

CHAPTER 7 SUSTAINABILITY IN THE EPIGENETICS MARKET: AN ESG PERSPECTIVE



Introduction to ESG Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market Sustainability Practices in Pharmaceuticals Manufacturing Sustainable Packaging Key ESG Issues in Epigenetics Research Tools Market ESG Risk Ratings Score -- Understanding the Data Concluding Remarks

CHAPTER 8 APPENDIX

Methodology Sources **Abbreviations Company Profiles** ACTIVE MOTIF INC. **BIO-RAD LABORATORIES INC. BIO-TECHNE** BRISTOL-MYERS SQUIBB CO. DAIICHI SANKYO CO. LTD. EXACT SCIENCES CORP. **GUARDANT HEALTH** HOLOGIC INC. LES LABORATOIRES SERVIER **MERCK KGAA** NUCLEIX PROMEGA CORP. QIAGEN **REVVITY INC. (PERKINELMER)** THERMO FISHER SCIENTIFIC INC.



List Of Tables

LIST OF TABLES

Summary Table : Global Market for Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029 Table 1 : Techniques, Advantages and Disadvantages of Common DNA Methylation Analysis Methods Table 2 : Types of Noncoding (ncRNAs) Table 3 : Key Programs/Consortiums to Support Epigenetic Research Table 4 : Epigenetic Biomarker-based Blood Tests Currently Under Clinical **Development** Table 5 : Companies Developing Products Based on Epigenome Editing Platforms Table 6 : BET Inhibitors in Late-Stage Clinical Trials Table 7 : Menin Inhibitors in Clinical Trials Table 8 : Novel Epigenetic Therapeutic Candidates in Clinical Trials Phase 2 and Above Table 9 : Global Market for Epigenetics Research Tools and Reagents, by Study Method, Through 2029 Table 10 : Commercially Available Epigenetic Biomarker-based IVDs for Colorectal Cancer Table 11 : Commercially Available Epigenetic Biomarker-based IVDs for Bladder Cancer Table 12 : Commercially Available Epigenetic Biomarker-based IVDs for Cervical Cancer Table 13 : Commercially Available Epigenetic Biomarker-based IVDs for Other Indications Table 14 : FDA Breakthrough Device Designated Epigenetic Biomarker-based Clinical Assays Currently Undergoing Clinical Validation Table 15 : Global Market for Epigenetic Biomarker-based IVDs, by Clinical Indication, Through 2029 Table 16 : Commercially Available DNMT Inhibitors Table 17 : Commercially Available HDAC Inhibitors Table 18 : Commercially Available IDH Inhibitors Table 19 : Commercially Available EZH2 Inhibitors Table 20: Global Market for Epigenetic Therapeutics, by Drug Class, Through 2029 Table 21 : Global Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, Through 2029 Table 22 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029



Table 23 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029

Table 24 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029

Table 25 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029

Table 26 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029

Table 27 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029

Table 28 : RoW Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029

Table 29 : Global Market Shares of Epigenetic Biomarkers-based IVDs, by Company, 2023

- Table 30 : Commercially Available Epigenetics-Targeted Drugs
- Table 31 : Key Sustainability Practices in the Pharmaceuticals Industry
- Table 32 : ESG Risk Ratings of Key Companies in the Epigenetics Market, 2024
- Table 33 : Ethos Impact Inc. Score Card for Key Companies in the Epigenetics Market, 2024
- Table 34 : Information Sources for this Report
- Table 35 : Abbreviations Used in the Report
- Table 36 : Active Motif Inc.: Company Snapshot
- Table 37 : Active Motif Inc.: Product Portfolio
- Table 38 : Active Motif Inc.: News/Key Developments, 2022
- Table 39 : Bio-Rad Laboratories Inc.: Company Snapshot
- Table 40 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
- Table 41 : Bio-Rad Laboratories Inc.: Product Portfolio
- Table 42 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023 and 2024
- Table 43 : Bio-Techne: Company Snapshot
- Table 44 : Bio-Techne: Financial Performance, FY 2022 and 2023
- Table 45 : Bio-Techne: Product Portfolio
- Table 46 : Bio-Techne: News/Key Developments, 2023
- Table 47 : Bristol-Myers Squibb Co.: Company Snapshot
- Table 48 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
- Table 49 : Bristol-Myers Squibb Co: Product Portfolio
- Table 50 : Daiichi Sankyo Co. Ltd.: Company Snapshot
- Table 51 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
- Table 52 : Daiichi Sankyo Co. Ltd.: Product Portfolio
- Table 53 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2024



- Table 54 : Exact Sciences Corp.: Company Snapshot
- Table 55 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
- Table 56 : Exact Sciences Corp.: Product Portfolio
- Table 57 : Exact Sciences Corp.: News/Key Developments, 2023 and 2024
- Table 58 : Guardant Health: Company Snapshot
- Table 59 : Guardant Health: Financial Performance, FY 2022 and 2023
- Table 60 : Guardant Health: Product Portfolio
- Table 61 : Guardant Health: News/Key Developments, 2023 and 2024
- Table 62 : Hologic Inc.: Company Snapshot
- Table 63 : Hologic Inc.: Financial Performance, FY 2023 and 2024
- Table 64 : Hologic Inc.: Product Portfolio
- Table 65 : Les Laboratoires Servier: Company Snapshot
- Table 66 : Les Laboratoires Servier: Financial Performance, FY 2022 and 2023
- Table 67 : Les Laboratoires Servier: Product Portfolio
- Table 68 : Les Laboratoires Servier: News/Key Developments, 2023 and 2024
- Table 69 : Merck KGaA: Company Snapshot
- Table 70 : Merck KGaA: Financial Performance, FY 2022 and 2023
- Table 71 : Merck KGaA: Product Portfolio
- Table 72 : Merck KGaA: News/Key Developments, 2023 and 2024
- Table 73 : Nucleix: Company Snapshot
- Table 74 : Nucleix: Product Portfolio
- Table 75 : Nucleix: News/Key Developments, 2023 and 2024
- Table 76 : Promega Corp.: Company Snapshot
- Table 77 : Promega Corp.: Product Portfolio
- Table 78 : Promega Corp.: News/Key Developments, 2023
- Table 79 : Qiagen: Company Snapshot
- Table 80 : Qiagen: Financial Performance, FY 2022 and 2023
- Table 81 : Qiagen: Product Portfolio
- Table 82 : Qiagen: News/Key Developments, 2023 and 2024
- Table 83 : Revvity Inc. (PerkinElmer): Company Snapshot
- Table 84 : Revvity Inc. (PerkinElmer): Financial Performance, FY 2022 and 2023
- Table 85 : Revvity Inc. (PerkinElmer): Product Portfolio
- Table 86 : Revvity Inc. (PerkinElmer): News/Key Developments, 2023
- Table 87 : Thermo Fisher Scientific Inc.: Company Snapshot
- Table 88 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
- Table 89 : Thermo Fisher Scientific Inc.: Product Portfolio
- Table 90 : Thermo Fisher Scientific Inc.: News/Key Developments, 2024



List Of Figures

LIST OF FIGURES

Summary Figure : Global Market Shares of Epigenetics Research Tools and Reagents,

IVDs and Therapeutics, by Product Type, 2023

Figure 1 : Market Dynamics of Epigenetics

Figure 2 : Estimated New Cancer Cases Globally, 2022, 2045 and 2050

Figure 3 : Global Blood Cancer Incidence, by Cancer Type, 2022 vs. 2045

Figure 4 : PubMed Article Count: "Epigenetic," 2018–2024

Figure 5 : Overcoming Barriers in the Clinical Application of Epigenetics

Figure 6 : PubMed Article Count: "Epitranscriptomic" and "RNA Modification," 2021-2024

Figure 7 : Trends in Clinical Trials for Epigenetic Therapeutic Agents, by Drug Class, as of December 2024

Figure 8 : Global Market Shares of Epigenetics Research Tools and Reagents, by Study Method, 2023

Figure 9 : Global Market Shares of Epigenetic Biomarker-based IVDs, by Clinical Indication, 2023

Figure 10 : Global Market Shares of Epigenetic Therapeutics, by Drug Class, 2023

Figure 11 : Global Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, 2023

Figure 12 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023

Figure 13 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023

Figure 14 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023

Figure 15 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023

Figure 16 : Worldwide Incidence of Blood Cancer Cases, by Region, 2022

Figure 17 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents,

IVDs and Therapeutics, by Product Type, 2023

Figure 18 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents,

IVDs and Therapeutics, by Country, 2023

Figure 19 : RoW Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023

Figure 20 : Principle Competitive Factors in Epigenetics Research Tools Market Figure 21 : Global Market Shares of Leading Manufacturers of Epigenetics-Targeted



Therapeutics, 2023

Figure 22 : Selected Factors Driving ESG Figure 23 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023 Figure 24 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023 Figure 25 : Bio-Techne: Revenue Share, by Business Unit, FY 2023 Figure 26 : Bio-Techne: Revenue Share, by Country/Region, FY 2023 Figure 27 : Bristol-Myers Squibb Co: Revenue Share, by Business Unit, FY 2023 Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023 Figure 29 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023 Figure 30 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Country/Region, FY 2023 Figure 31 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023 Figure 32 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023 Figure 33 : Guardant Health: Revenue Share, by Business Unit, FY 2023 Figure 34 : Guardant Health: Revenue Share, by Country/Region, FY 2023 Figure 35 : Hologic Inc.: Revenue Share, by Business Unit, FY 2024 Figure 36 : Hologic Inc.: Revenue Share, by Country/Region, FY 2024 Figure 37 : Les Laboratoires Servier: Revenue Share, by Business Unit, FY 2023 Figure 38 : Les Laboratoires Servier: Revenue Share, by Region, FY 2023 Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023 Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023 Figure 41 : Qiagen: Revenue Share, by Business Unit, FY 2023 Figure 42 : Qiagen: Revenue Share, by Country/Region, FY 2023 Figure 43 : Revvity Inc. (PerkinElmer): Revenue Share, by Business Unit, FY 2023 Figure 44 : Revvity Inc. (PerkinElmer): Revenue Share, by Country/Region, FY 2023 Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023 Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023



I would like to order

Product name: Epigenetics: Technologies and Global Markets

Product link: https://marketpublishers.com/r/E7E9887223A0EN.html

Price: US\$ 4,650.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/E7E9887223A0EN.html</u>